FI900178A0 - Kompositioner och foerfarande foer behandling eller foerhindrande av infektioner hos djur. - Google Patents

Kompositioner och foerfarande foer behandling eller foerhindrande av infektioner hos djur.

Info

Publication number
FI900178A0
FI900178A0 FI900178A FI900178A FI900178A0 FI 900178 A0 FI900178 A0 FI 900178A0 FI 900178 A FI900178 A FI 900178A FI 900178 A FI900178 A FI 900178A FI 900178 A0 FI900178 A0 FI 900178A0
Authority
FI
Finland
Prior art keywords
csf
infektioner
djur
foerhindrande
behandling
Prior art date
Application number
FI900178A
Other languages
English (en)
Inventor
Thomas C Boone
Allan L Miller
Jeffrey W Andersen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of FI900178A0 publication Critical patent/FI900178A0/fi
Priority to FI945325A priority Critical patent/FI103342B1/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Filling Or Discharging Of Gas Storage Vessels (AREA)
  • Element Separation (AREA)
FI900178A 1988-05-13 1990-01-12 Kompositioner och foerfarande foer behandling eller foerhindrande av infektioner hos djur. FI900178A0 (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI945325A FI103342B1 (fi) 1988-05-13 1994-11-11 Menetelmä G-CSF:n eristämiseksi ja puhdistamiseksi

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19385788A 1988-05-13 1988-05-13
US34801189A 1989-05-09 1989-05-09
PCT/US1989/002057 WO1989010932A1 (en) 1988-05-13 1989-05-12 Compositions and method for treating or preventing infections in animals

Publications (1)

Publication Number Publication Date
FI900178A0 true FI900178A0 (fi) 1990-01-12

Family

ID=26889429

Family Applications (1)

Application Number Title Priority Date Filing Date
FI900178A FI900178A0 (fi) 1988-05-13 1990-01-12 Kompositioner och foerfarande foer behandling eller foerhindrande av infektioner hos djur.

Country Status (12)

Country Link
US (1) US5849883A (fi)
EP (2) EP0347041A3 (fi)
JP (1) JP2796388B2 (fi)
KR (1) KR0133561B1 (fi)
AT (1) ATE452190T1 (fi)
AU (3) AU636127B2 (fi)
DE (1) DE68929566D1 (fi)
DK (1) DK175245B1 (fi)
FI (1) FI900178A0 (fi)
NO (1) NO300217B1 (fi)
NZ (1) NZ229098A (fi)
WO (1) WO1989010932A1 (fi)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
KR0133561B1 (ko) 1988-05-13 1998-04-21 스티븐 엠. 오드레 과립구 군체 자극인자의 정제방법
JPH04502164A (ja) * 1989-10-10 1992-04-16 アムジエン・インコーポレーテツド 犬科・猫科動物における感染の治療または予防のための化学組成物及び方法
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5336488A (en) * 1991-08-07 1994-08-09 American Cyanamid Company Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
JPH10505232A (ja) * 1994-08-19 1998-05-26 エンブレクス，インコーポレイテッド 鳥類骨髄単球性成長因子を用いる鳥類の処置方法
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996040912A1 (en) 1995-06-07 1996-12-19 Amgen Inc. Ob protein compositions and method
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
DK0988861T3 (da) * 1998-08-17 2004-04-19 Pfizer Prod Inc Stabiliserede proteinpræparater
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
PT1129720E (pt) 2000-02-29 2004-08-31 Pfizer Prod Inc Factor estimulador de colonias de granulocitos estabilizado
WO2002020767A2 (en) * 2000-09-08 2002-03-14 Massachusetts Institute Of Technology G-csf analog compositions and methods
US7557195B2 (en) 2002-03-20 2009-07-07 Biopolymed, Inc. Stoichiometric conjugates of biocompatible polymers at the unpaired cysteine residue of the wild-type G-CSF
AU2002345829A1 (en) * 2002-06-24 2004-01-06 Dr. Reddy's Laboratories Ltd. Process for preparing g-csf
NZ543392A (en) * 2003-05-09 2009-02-28 Schering Ag Treatment of inflammatory respiratory diseases e.g. SARS, ARDS, IRDS
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
RU2385878C2 (ru) 2004-02-11 2010-04-10 Амилин Фармасьютикалз, Инк. Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
WO2005077094A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
WO2006042242A2 (en) 2004-10-08 2006-04-20 Amylin Pharmaceuticals, Inc. Amylin family polypeptide- 6 (afp- 6) analogs and methods of making and using them
ATE544463T1 (de) 2004-11-05 2012-02-15 Univ Northwestern Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen
NZ555533A (en) 2004-12-13 2010-03-26 Amylin Pharmaceuticals Inc Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
CA2597649A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
MX2007015156A (es) 2005-06-01 2008-02-15 Maxygen Holdings Ltd Polipeptidos g-csf pegilados y metodos para la produccion de los mismos.
DE102005033250A1 (de) † 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
KR100735784B1 (ko) * 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
US9176145B2 (en) * 2006-07-21 2015-11-03 Femalon S.P.R.L. Kit for predicting implantation success in assisted fertilization
WO2008116470A1 (en) * 2007-03-26 2008-10-02 Drugrecure Aps Enhancing pulmonary host defence via administration of granulocyte- colony stimulating factor
EP2197919B1 (en) 2007-08-27 2014-04-09 ratiopharm GmbH Liquid formulation of g-csf conjugate
EP2281827B1 (en) 2008-05-08 2013-08-21 Ajinomoto Co., Inc. Protein refolding method
JP5680534B2 (ja) * 2008-07-23 2015-03-04 イーライ リリー アンド カンパニー 修飾されているウシｇ−ｃｓｆポリペプチドおよびそれらの使用
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
CN102482321B (zh) 2009-06-22 2015-06-17 安姆根有限公司 使用化学控制的氧化还原态重折叠蛋白质
AU2010266093B2 (en) 2009-06-25 2013-06-27 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
US20130040877A1 (en) 2009-09-18 2013-02-14 Novo Nordisk A/S Long-acting y2 receptor agonists
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
CN102892780B (zh) 2010-03-17 2015-07-29 通益制药有限公司 获得生物活性的重组人g-csf的方法
RU2487885C2 (ru) * 2010-07-20 2013-07-20 Зао "Биокад" Способ крупномасштабного получения, выделения и очистки рекомбинантного гранулоцитарного колониестимулирующего фактора человека
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
EP2675460A4 (en) 2011-02-18 2014-07-09 Kythera Biopharmaceuticals Inc TREATMENT OF FAT TISSUE UNDER CHIN
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
HUP1200172A2 (en) * 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies
US20150141336A1 (en) 2012-05-29 2015-05-21 Novo Nordisk A/S Pancreatic Peptide Compounds and Use
US9982012B2 (en) 2013-03-29 2018-05-29 Dr. Reddy's Laboratories Limited Refolding of granulocyte colony stimulating factor
CA3077215A1 (en) * 2017-10-11 2019-04-18 Elanco Us Inc. Porcine g-csf variants and their uses
WO2020234742A1 (en) * 2019-05-20 2020-11-26 Lupin Limited Granulocyte colony stimulating factor purification
US20220251137A1 (en) * 2019-07-09 2022-08-11 Jennifer Renee HOPP Temperature-controlled purification of granulocyte-colony stimulating factor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2438821A1 (fr) * 1978-10-13 1980-05-09 France Etat Dispositif d'allumage a fil chaud de securite
US4618600A (en) * 1984-04-19 1986-10-21 Biotechnology Research Associates, J.V. Novel polypeptide diuretic/vasodilators
JPS6145010A (ja) * 1984-08-08 1986-03-04 Setsuji Umezaki 埋立地の造成方法
JPH0615477B2 (ja) * 1985-02-08 1994-03-02 中外製薬株式会社 感染防禦剤
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4721420A (en) * 1985-09-03 1988-01-26 Arthur D. Little, Inc. Pipeline transportation of coarse coal-liquid carbon dioxide slurry
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
WO1988008428A1 (en) * 1987-04-28 1988-11-03 Amgen Inc. Method for purifying granulocyte/macrophage colony stimulating factor
ATE121418T1 (de) * 1987-10-23 1995-05-15 Schering Corp Verfahren zur proteinreinigung.
KR0133561B1 (ko) 1988-05-13 1998-04-21 스티븐 엠. 오드레 과립구 군체 자극인자의 정제방법

Also Published As

Publication number Publication date
KR900701824A (ko) 1990-12-04
KR0133561B1 (ko) 1998-04-21
DK9290A (da) 1990-03-09
DK175245B1 (da) 2004-07-19
US5849883A (en) 1998-12-15
EP0719860B1 (en) 2009-12-16
DK9290D0 (da) 1990-01-12
AU4197293A (en) 1993-10-28
NZ229098A (en) 1992-10-28
NO900185D0 (no) 1990-01-12
DE68929566D1 (de) 2010-01-28
WO1989010932A1 (en) 1989-11-16
AU636127B2 (en) 1993-04-22
AU4197393A (en) 1993-10-28
EP0347041A3 (en) 1990-11-22
NO900185L (no) 1990-03-12
AU4781290A (en) 1990-11-15
NO300217B1 (no) 1997-04-28
JP2796388B2 (ja) 1998-09-10
ATE452190T1 (de) 2010-01-15
JPH02504521A (ja) 1990-12-20
EP0347041A2 (en) 1989-12-20
AU661172B2 (en) 1995-07-13
EP0719860A1 (en) 1996-07-03

Similar Documents

Publication Publication Date Title
FI900178A0 (fi) Kompositioner och foerfarande foer behandling eller foerhindrande av infektioner hos djur.
DK47189D0 (da) Bredspektret konserveringsmiddel med synergistisk biocidvirkning
FI953593A0 (fi) G-CSF-analogikoostumuksia ja menetelmiä
DE3174516D1 (en) 3-(p-alkylsulfonylphenyl)-and 3-(p-alkylsulfinylphenyl)oxazolidinone derivatives as anti-bacterial agents
DK16890A (da) Antiviral eller antibakteriel forbindelse og frem gangsmaade til anvendelse heraf
ES8507535A1 (es) Acidos 7-amino-1-ciclopropil-6,8-difluor-1,4-dihidro-4-oxo-quinolincarboxilicos
ATE73342T1 (de) Polypeptid-wachstumsfaktor aus milch.
DK0608912T3 (da) Synergistiske mikrobicide sammensætninger
AU633714B2 (en) New uses of l-deprenyl and compositions for same
BG104089A (en) Dolastatine 15 derivatives
ES2055684T5 (es) Composicion farmaceutica que contiene un factor estimulante de colonias de granulocitos para el tratamiento de la leucopenia.
FR2751879B1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
IL88971A0 (en) Disubstituted pyridines,their preparation and pharmaceutical compositions containing them
AU2696584A (en) Pharmaceutical compositions of anti-pancreatic inflammatory effect
GEP20022840B (en) Form VI 5,6-Dichloro-2-(Isopropylamino)-1-(Beta-L-Ribofuranosyl-1H-Benzimidazole), Method for Their Production, Composition for Treating Virus Infections and Methods for Treatment
MY101807A (en) 2-azolylmethyl-3-difluorobenzyloxy-2, 3-dihydrofluo robenzo[b]thiopenes, process for their preparation and compositions containing them.
MY110041A (en) Composition and method of treating hepatitis c

Legal Events

Date Code Title Description
FD Application lapsed
FD Application lapsed

Owner name: AMGEN INC.